effective in patients with adenovirus-induced haemorrhagic cystitis (Kawakami et al., 1997; Kitabayashi et al., 1994) , although it is ineffective for patients who are at high risk for disseminated adenovirus disease (Bordigoni et al., 2001; Hatakeyama et al., 2003) , and cidofovir rather than vidarabine has been recommended for these patients. Thus, vidarabine therapy has been controversial, and the mechanism of action of vidarabine is unknown. Therefore, we investigated effects of vidarabine in vitro on adenovirus type 11 isolated from healthy children with haemorrhagic cystitis.
Materials and methods

Cells and viruses
HEp-2 cells and two strains of adenovirus type 11 isolated from urine of children with haemorrhagic cystitis (Hiroshima City Institute of Public Health) were used in this study. HEp-2 cells were grown and maintained in Eagle's minimum essential medium (MEM) supplemented with 5% and 2% fetal bovine serum, respectively. 
Introduction
The two strains of adenovirus type 11 were grown in HEp-2 cells, and the virus stocks were prepared from infected HEp-2 cells after three cycles of freezing and thawing the infected cultures.
Drugs
Vidarabine (Mochida Pharmaceutical Co., Japan) and acyclovir (Sigma, Mo., USA) were dissolved at 10 mg/ml in dimethylsulphoxide.
Yield reduction assay
The inhibitory activity of vidarabine on anti-adenovirus type 11 replication was examined in a yield reduction assay. Monolayers of HEp-2 cells in 25 cm 2 plastic flasks were infected with 1×10 6 , a 50% tissue culture infectious dose (TCID 50 )/200 µl of adenovirus type 11, for 1 h. The cells were washed twice with MEM and incubated in maintenance medium containing various concentrations of vidarabine at 37°C for 24 h. The cultures were frozen and thawed three times and then centrifuged at 3500 rpm for 20 min. Virus titres in the supernatants were determined by measurement of the TCID 50 value on HEp-2 cells. Briefly, HEp-2 cells in 24-well plates were infected with 100 µl of sequentially diluted supernatants for 1 h. The cells were washed twice with MEM and incubated in maintenance medium at 37°C for 7 days. The cytopathic effect was observed under a dissecting microscope and TCID 50 values were determined.
Cytotoxicity assay
Cytotoxicity was examined by the growth inhibition of HEp-2 cells. HEp-2 cells were seeded at a concentration of 2.5×10 4 cells/well in 24-well plates and grown at 37°C for 2 days. The culture medium was replaced with fresh medium containing vidarabine or acyclovir at various concentrations, and cells were grown for a further day. The cells were treated with trypsin, and the number of viable cells was determined by the trypan blue-exclusion test.
Analysis of viral protein synthesis
The effects of vidarabine and acyclovir on viral protein synthesis in HEp-2 cells infected with adenovirus were examined. The cells were infected with adenovirus at 1 TCID 50 /cell and incubated in the presence of [ 35 S] methionine and cysteine (37 Tbq/mmol, Amersham Biosciences, NJ, USA) and various concentrations of vidarabine or acyclovir for 20 h at 37°C. The labelled cells were lysed with 20 mM Tris buffer (pH 8.0, containing 150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulphate, 1 mM phenylmethylsulphonyl fluoride), and viral proteins were immunoprecipitated with immunoglobulin for human use (Miles Inc., Ind., USA) (Kurokawa et al., 1995) . The immunoprecipitates and total cell lysates were subjected to SDS-polyacrylamide gel electrophoresis followed by fluorography (Kurokawa et al., 1990 (Kurokawa et al., , 1995 . Protein bands on the exposed films were scanned with a Bio-Rad Image Analysis System with a Fluor-S TM MultiImager (Bio-Rad Laboratories, Inc., Calif., USA) and quantitatively analysed by Macintosh software, Multi-Analyst 1.0.
Results
The anti-adenovirus activity of vidarabine and acyclovir against the two strains of adenovirus type 11 was examined by a yield reduction assay using HEp-2 cells. The two strains used were similarly susceptible to vidarabine, and vidarabine dose-dependently inhibited viral replication, as shown in Figure 1 . At a vidarabine concentration of 300 µg/ml, the viral growth was 0.003% and 0.0005% of the control, 1.8×10 6 and 1.5×10 6 TCID 50 . In contrast, acyclovir had no effect on replication even at a concentration of 300 µg/ml (data not shown). When vidarabine was examined for cytotoxicity against HEp-2 cells, the 50% cytotoxic concentration (CC 50 ) value for HEp-2 cells was more than 300 µg/ml, and the cytotoxicity at this concentration was 17.3% of untreated cells. Vidarabine specifically inhibited replication of adenovirus type 11 without cytotoxicity in this assay condition.
Synthesis of adenovirus proteins was compared in the presence of vidarabine and acyclovir. With regards to the profile of protein synthesis in host cells, vidarabine at 10-300 µg/ml and acyclovir at 5-100 µg/ml did not inhibit the synthesis of host cell total proteins without immunoprecipitation of radiolabelled proteins ( Figure 2A ). As shown Results of the yield reduction assay in each concentration of vidarabine are shown as the percent TCID 50 of untreated cultures. Two strains ( ) and ( ) of adenovirus type 11 were used and their virus yields were 1.8×10 6 and 1.5×10 6 TCID 50 /ml, respectively.
in Figure 2B , after immunoprecipitation of radiolabelled proteins, vidarabine at 10-300 µg/ml dose-dependently inhibited the synthesis of the 50, 72, 87, 125 and 140 kDa viral proteins, but acyclovir, at concentrations of up to 100 µg/ml, did not. Thus, vidarabine selectively inhibited the synthesis of adenovirus proteins without apparent cytotoxicity. The intensities of viral protein bands in the autoradiograms were quantitatively analysed to compare the modes of dose-dependent reduction of protein bands and virus yields. As shown in Figure 2C , the amounts of proteins were dose-dependently reduced -the levels of these proteins were 0-40% of the untreated control at a dose of 300 µg/ml. In contrast, no reduction was seen in the presence of acyclovir.
Discussion
Vidarabine has been reported to be effective for treatment of adenovirus-induced haemorrhagic cystitis in immunocompromised patients, for whom a specific antiviral therapy has not yet been established. Because the mechanism of the anti-adenovirus action of vidarabine is unknown, we investigated the effects of vidarabine on adenovirus type 11 isolated from clinical samples. We found that vidarabine showed anti-adenovirus type 11 activity in vitro.
The cytotoxicity of vidarabine was examined by its inhibition of viral growth and protein synthesis. The maximum concentration of vidarabine used was 300 µg/ml, and the viability of HEp-2 cells in this concentration was 82.7% of the control. HEp-2 cells appeared to be swollen under the microscope at a vidarabine concentration of 300 µg/ml. These morphological changes suggested that vidarabine might slightly affect HEp-2 cells. However, there was no difference between vidarabine and acyclovir in the synthesis of host cell proteins at all concentrations examined. This indicated the protein synthesis in cells was not reduced nor influenced by treatment with vidarabine. Thus, our results indicated that vidarabine specifically inhibited adenovirus type 11 replication without obvious cytotoxicity in vitro.
Immunoprecipitation showed that the synthesis of viral proteins was dose-dependently reduced in cells infected with adenovirus type 11 in the presence of vidarabine compared with its absence. We supposed that 50, 72, 87, 125 and 140 kDa proteins corresponded to fibre, DNAbinding protein, pre-terminal protein, hexon and E2-coded polymerase, respectively, from their molecular weights (Shenk, 1996; Wadell, 1979) . DNA-binding protein, preterminal protein and E2-coded polymerase are early proteins, and the synthesis of these proteins was reduced to 20-40% at a vidarabine concentration of 300 µg/ml. On the other hand, fibre and hexon are late proteins, and the synthesis of these proteins was effectively inhibited at a vidarabine concentration of 30 µg/ml and not detected at a dose of 300 µg/ml. These results indicate that vidarabine acted less on the synthesis of early proteins but rather on those after DNA replication. We supposed that this differential inhibitory effect results in the absence of adenovirus DNA replication in the presence of vidarabine. Since the synthesis of viral RNA was dose-dependently reduced by vidarabine (data not shown), it is possible that vidarabine inhibits the replication process before viral DNA synthesis.
After intravenous infusion, vidarabine is rapidly deaminated to 9-β-D-arabinofuranosyl hypoxanthine (Ara-Hx) as the principal metabolite. The kidney is the primary route of elimination: approximately 2% of the dose was excreted in the urine as vidarabine and approximately 50% as AraHx (Buchanan et al., 1980) . Ara-Hx has been reported to have in vitro antiviral activity, but this activity is only about 2-10% of that of vidarabine (Connor et al., 1974; Gephart et al., 1981; Miller et al., 1968; Preiksaitis et al., 1981; Shope et al., 1983) .
Clinically, vidarabine has been used at the dosage of 10 mg/kg intravenously once daily for 5 days (Kawakami et al., 1997; Vianelli et al., 2000) . At this dosage, if the volume of urine is 1 ml/kg/h, about 8.3 µg/ml vidarabine and about 208.3 µg/ml Ara-Hx are excreted in the urine, assuming that the antiviral activity of Ara-Hx in vivo is 2-10% of vidarabine and the urine concentration of vidarabine is about 12.5-30 µg/ml. Our results show that viral replication was inhibited to less than 40% of the untreated control at a vidarabine concentration of 10 µg/ml and to less than 20% at 30 µg/ml. However, we expect that the concentration of vidarabine in the bladder is higher than these values, because the routes to the bladder are not only via urine but also via blood flow, and, in practice, in vivo vidarabine may be effective for adenovirus-induced haemorrhagic cystitis.
Vidarabine is from the older generation of antiviral agents and may not be suitable for patients with renal dysfunction because of poor solubility of the molecule in water. Recently, cidofovir rather than vidarabine has been recommended for these patients. But, on the other hand, vidarabine has been reported to be effective for patients with adenovirus-induced haemorrhagic cystitis (Kawakami et al., 1997; Kitabayashi et al., 1994) ; our results support the efficacy of vidarabine.
